FDA approves new larger production setup for Genmab drug

After the US health authorities approved a new production setup at Horizon Therapeutics, which holds the rights to Genmab's drug Tepezza, the company expects that current supply-related issues will soon be resolved.

Photo: PR / Genmab

With April 1 as the starting point, Horizon Therapeutics expects to put a stop to the supply issues which have affected the company's new and highly popular launch Tepezza since December last year, which the firm states in a press release.

The firm's solution, as it turns out, is that it has received approval from the US Food and Drug Administration (FDA) to introduce a new production setup, which allows Horizon Therapeutics to produce more of the drug itself, rather than outsourcing this task to contractors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs